羟基喜树碱联合FOLFOX4方案二线治疗晚期胃癌

目的：评价羟基喜树碱（HCPT）联合FOLFOX4方案作为二线治疗晚期胃癌的疗效和毒性。方法：19例晚期胃癌患者,先给予奥沙利铂（L-OHP）85mg/m^2静脉滴注2h,第1天;亚叶酸钙（CF）200mg/m^2静脉滴注2h;随后5-FU400mg/m^2静脉快速冲入,5-FU600mg/m^2静脉滴注22h,第1～2天;HCPT10mg静脉滴注3h,第1～2天。2周重复,至少2个周期后评价疗效。结果：全组19例患者,17例可以进行疗效评价,完全缓解1例,部分缓解6例,稳定4例,进展6例,总有效率为41.2%。12例存在肝脏转移患者中,肝转移灶有效率50%。毒副作用主要是骨髓抑制、恶心呕吐、神经毒性,无化疗相关死亡。结论：羟基喜树碱联合FOLFOX4方案二线治疗晚期胃癌疗效肯定,特别是对于肝转移灶有效率高,毒副作用能够耐受。

Clinical analysis of HCPT plus FOLFOX4 regimen as salvage therapy for patients with advanced gastric cancer

Objective:To evaluate the efficacy as well as side effects of HCPT plus FOLFOX4 regimen as salvage therapy for patients with advanced gastric cancer.Methods:A total of 19 patients with advanced gastric cancer received HCPT plus FOLFOX4 as salvage therapy,in detail,oxaliplatin 85mg/m2 was given intravenously on day 1,CF 200mg/m2,5-FU 400mg/m2 given in bolus immediately after CF,days 1-2;5-FU 600mg/m2 given continuously after bolus for 22 hours on days 1-2.HCPT given intravenously at dosage of 10mg/m2,on days 1-2.Therapeutic effects were evaluated at least after two cycles of treatment.Results:Seventeen cases among the 19 cases were valid for response evaluation,with CR 1,PR 6,SD 4,PD 6.The response rate was 41.2%.For the 12 patients with liver metastasis,response rate of the liver foci was 50%.The main toxicities were bone marrow suppression,nausea and vomiting,neurological toxicity;there was no chemotherapy-related death.Conclusion:The combination regimen with HCPT plus FOFLOX4 regimen is effective as salvage therapy for patients with advanced gastric cancer,especially for liver metastatic foci,and the side effects were tolerable and manageable.